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Abstract
Background: Resection and reconstruction of the inferior vena cava (IVC) is occasionally required in the
surgical treatment of intra-abdominal tumours. IVC reconstruction can be performed with biological or
synthetic graft material, with most centres preferring synthetic grafts. In spite of the potential advantages
of biological grafts in terms of handling characteristics, and safety, very limited data are available about
their use in patients requiring an IVC resection.
Methods: Medical records of 32 patients who underwent an IVC resection and reconstruction from 1990
and 2011 with autogenous peritoneo-fascial (N = 22) and bovine pericardial (N = 10) grafts were reviewed.
Results: A tangential resection with patch repair was performed in 10 patients, whereas in the remain-
ing 22 it was necessary to resect and replace a segment or all of the retrohepatic IVC. A concomitant
liver resection was performed in 14 patients, nephrectomy in 10 and pancreaticoduodenectomy in 2
patients. There were no acute or late complications related to graft thrombosis or infection. Three
patients died as a consequence of multi-organ failure. Overall survival at 1 and 5 years was 78% and
48%, respectively.
Conclusions: The preferential use of synthetic grafts in IVC replacement is not evidence based. Selec-
tion of an appropriate prosthetic graft for IVC reconstruction should be based on the safety and its
handling features. The use of biological grafts for IVC repair is a valid alternative to current synthetic
materials and may in fact be superior in terms of biocompatability, ease of handling, reduced rate of
infection and improved long-term patency without permanent anticoagulation.
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Introduction
Several series have reported on the safety and satisfactory onco-
logical outcomes of resection for tumours that originate from or
infiltrate the inferior vena cava (IVC).1–5 The optimal manage-
ment of the IVC after resection is controversial,6 with the use of
patch or interposition grafting for IVC reconstruction the most
commonly used approach.1–5
A variety of materials, such as biological (autologous or heter-
ologous) and synthetic materials, have been proposed as grafts for
IVC reconstruction.7 The synthetic material, polytetrafluoroeth-
ylene (PTFE) has become the most commonly used material for
IVC replacement1–5 because it is readily available and comes in a
variety of diameters and lengths. Given the potential risk of infec-
tion and thrombosis of synthetic grafts, the optimal material for
IVC reconstruction is still debated and the search for improved
graft material is still ongoing.7
Biological grafts have been proposed as an alternative to PTFE,
because of their biocompatibility, reliable long-term patency and
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low risk of infection.7,8 However, data regarding the use of biologic
grafts for reconstruction of the IVC are very limited. The use of
two types of biological grafts, autogenous peritoneo-fascial (APF),
and bovine pericardium for IVC reconstruction are described in
the present study.
Patients and methods
The medical records of 32 patients who underwent IVC recon-
struction with biological material between 1990 and 2011 were
reviewed. Institutional review board approval was obtained for
this study. Short- and long-term outcomes, cumulative patency of
IVC replacement and survival were assessed. Reconstruction of
the IVC was performed with an APF graft in 22 patients and
bovine pericardium in 10 patients. No IVC reconstruction with a
synthetic graft was performed during the study period. The crea-
tion of the conduit was carried out intra-operatively after the size
of the patient’s IVC was determined. When the APF graft was
used, a flap of parietal peritoneum backed by the posterior rectus
sheath was sharply dissected from the abdominal wall. The peri-
toneal surface was maintained on the luminal side and the graft
wrapped around a 20–22 Fr cylindrical sizing device to obtain the
appropriate diameter. Fashioning of the tube was completed by
staple transection using a 60-mm linear cutting vascular stapler.
The graft was then fixed with 2% glutaraldehyde solution soaked
for 10 min and the glutaraldehyde was removed with serial dilu-
tion in isotonic saline. The technique used for the construction of
the bovine pericardial graft is similar to APF. The bovine pericar-
dial leaflet is wrapped around a cylindrical sizing device to obtain
the appropriate diameter, and anastomosed longitudinally by a
vascular linear cutting stapler (Fig. 1).
In all patients, the IVC was resected and repaired under total
vascular exclusion. Isolated hypothermic perfusion was used
selectively for patients with liver disease and where long clamp
times were expected owing to the complexity of resection. The
type of caval resection and reconstruction varied according to
tumour infiltration of the IVC. A large number of patients were
able to have primary closure of their IVC without the need for a
graft and were not included in this study. When the IVC wall
involvement was longitudinal and less than 30% of its circumfer-
ence, a tangential resection with patch reconstruction was per-
formed.When involvement of the IVC was greater than 40% of its
circumference a caval segment was resected and replaced. The
anastomosis was performed in a standard fashion with a continu-
ous 3/0 polypropylene suture. Unfractionated heparin (5000 IU
every 12 h) was administered subcutaneously after the operation
until discharge. The patients were typically followed up every 3
months with a clinical examination, blood test and abdominal
imaging [computed tomography (CT) or magnetic resonance
imaging). At 1-year post-operatively, an individualized follow-up
protocol according to the tumour and patient characteristics was
used. Re-evaluation was done at the request of the primary phy-
sician or the oncology service based on clinical symptoms.
Imaging was obtained if patients developed symptoms of IVC
compression such as lower extremity oedema and scrotal oedema.
Morbidity was classified according to Dindo-Clavien classifica-
tion9 and operative mortality was defined as any death occurring
within 90 days after surgery. The results are presented as median
and ranges.
Results
A total of 32 patients underwent IVC graft reconstruction with
biological grafts during the study period. The demographic char-
acteristics are listed in Table 1. Indications for surgery were color-
ectal liver metastases in 5 patients, leiomyosarcoma in 8, renal cell
cancer in 11, adrenal cancer in 2, hepatocellular carcinoma (HCC)
in 1, intrahepatic cholangiocarcinoma in 2 and a gastrointestinal
stromal tumour in 1. IVC resection was performed with an
extended right hepatectomy in 4 patients, right hepatectomy in 2,
extended left hepatectomy in 1, minor liver resection in 7,
nephrectomy in 10 and pancreaticoduodenectomy in 2 patients.
The median operating time was 400 min (180–620) and the
median blood loss was 2000 ml (300–9000).A tangential resection
with patch repair was performed in 10 patients, whereas in the
remaining 22 it was necessary to resect and replace a circumfer-
ential segment, or all, of the retrohepatic IVC. Re-implantation of
the renal or hepatic vein was performed in 10 patients.
Post-operative outcome
Six major complications (grade  3a) occurred in six patients
(Table 2).One patient died of multi-organ failure after the onset of
acute respiratory distress syndrome and septic shock. The remain-
ing two patients died of acute liver failure leading to multi-organ
failure. In all these three patients, IVC replacement was associated
with a major liver resection. Non-lethal complications (grade 
Figure 1 Construction of the pericardial tube. A longitudinal suture is
performed by applying the linear reloadable stapler to the leaflet
wrapped around a syringe
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3a) in the other three patients included transient liver insufficiency,
biliary fistula and sepsis. There were no early or late complications
related to graft thrombosis or infection. Tumour infiltration of
the IVC was observed during the pathological examination of the
specimen in 24 patients, whereas in the remaining 8 patients the
tumour was adherent to the IVC without infiltration. Follow-up
CT scans were available for review in 26 of 32 patients at a median
follow-upof 40months after the IVC resection (Fig. 2).Nopatients
developed clinical signs of IVC compression or thrombosis. The
overall survival at 1 and 5 years was 78% and 48%, respectively.
Discussion
The ideal material for IVC reconstruction remains controversial.7
PTFE grafts have been reported to remain patent for several years,
but there are disadvantages to the use of PTFE, with the need for
long-term anticoagulation therapy and the risk of graft infection.
Biological grafts have been proposed as an alternative to PTFE in
cardiothoracic surgery for the reconstruction of the superior vena
cava.10 However, limited data are available about the use of
biological grafts for the reconstruction of the IVC.
The use of biological tissues dates back to the early days of
cardiovascular surgery, when the autologous vein was used in a
coronary artery bypass.7 A significant advance in the use of bio-
logical material came from the use of glutaraldehyde, which
enhances the structural stability, eliminates the antigenicity and
preserves the sterile tissue.11 Bovine pericardium treated with glu-
taraldehyde is one of the biological materials widely used in car-
diovascular surgery as a patch after arteriotomy andmore recently
Table 1 Patients and surgical characteristics
Variables
Gender (M/F) 21/11
Age (years) 58.5 (30–78)
Diagnosis
Renal cancer 11
Leiomiosarcoma 8
Colorectal metastases 5
Adrenal cancer 4
Cholangiocarcinoma 2
HCC 1
GIST 1
Operation time median (range) 400 (180–620)
IVC clamping time (min) median (range) 25 (8–60)
Associated surgical procedures
Nephrectomy 10
Hepatic resection (n) 14
Bisegmentectomy 5
Extended right hepatectomy 4
Right hepatectomy 2
Extended left hepatectomy 1
Segmentectomy 2
Whipple 2
Right hemicolectomy 1
Blood loss (ml) median (range) 3200 (300–9000)
HCC, hepatocellular carcinoma; GIST, gastrointestinal stromal tumour;
IVC, inferior vena cava.
Table 2 Post-operative complications
Variables N
Grade I
Wound infection 2
Grade II
Cardiac arrhythmia 1
Pneumonia 1
Chyle ascites 1
Infection 2
Transitory liver failure (Bil tot>3, PT-INR >1.5, on POD5) 3
Total minor complications (grade 1 + 2) 10
Grade III
Pleural effusion 1
Bile leak 1
Grade IV
Severe hepatic failure (requiring ICU admission) 2
Sepsis 1
MOF 3
Grade V (death) 3
Total major complications (grade 3 + 4 + 5) 7
Hospital stay (days) median (range) 8 (5–34)
PT-INR, prothrombin time-international normalized ratio; POD, post-
operative day; ICU, intensive care unit; MOF, multi-organ failure.
Figure 2 One-year post-operative computed tomography showing
excellent patency after inferior vena cava (IVC) replacement with an
autogenous peritoneo-fascial (APF) graft
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for major venous reconstruction. The commercially available
detoxified bovine pericardial flaps have strongly improved the
graft biocompatibility, providing heterologous tissue comparable
to autologous tissue. Bovine pericardium has several well-known
features. It has lower risks of infection and thrombosis when
compared with synthetic materials, and does not require long-
term anticoagulation.8,11 The commercially available bovine peri-
cardium is manufactured and processed to a consistent nominal
0.5 mm thickness, this reliable consistency makes it easy to suture
the graft to the vascular wall and has little suture line bleeding
after implantation. As bovine pericardium is a solid tissue,
without air spaces, ultrasound can be immediately used after
implantation to check for patency.8 Furthermore, bovine pericar-
dium is an acellular material, composed mainly of collagen, which
facilitates host cell migration and proliferation, accelerating tissue
regeneration and endothelialization.7,8 Finally, as bovine pericar-
dium is a fixed tissue, it has the advantage of off-the-shelf avail-
ability with a cost significantly lower than PTFE grafts.
Experimental use of peritonealized fascial grafts for the recon-
struction of artery and veins was initially described in the late
1960s.12 However, this graft was not considered for clinical prac-
tice until our group described the first experience in six patients.13
APF is readily available and the harvesting and fashioning of
the graft can be easily performed in a short time. Experimental
data have demonstrated that the inner peritoneal mesothelial
surface has a low thrombogenic potential and induces rapid
endothelialization.14,15
Infection after IVC replacement with PTFE has been shown to
be a rare occurrence in several large series. Even although the risk
of PTFE graft infection is low, there is increased concern where
IVC resection and reconstruction is performed in association with
a bilioenteric, colonic or pancreatic anastomosis.16 Furthermore,
in spite of a patency rate between 89–100% being reported in large
series of IVC reconstruction with PTFE, long-term anticoagula-
tion was necessary.1–4,17,18 This has led some authors to propose the
use of various forms of biological grafts including APF, bovine
pericardium and sutured superficial femoral vein panel graft for
IVC reconstruction because these biological grafts represent a
safer alternative to PTFE.13,19–21 Furthermore, from a technical
point of view both bovine pericardium and APF have many
features, which compare favourably with PTFE. The grafts can be
easily tailored to match the size of the native IVC even when the
diameter at the top and bottom of the graft are different. These
grafts have optimal handling features, minimal suture line bleed-
ing and a lower cost.
The results of the present series demonstrate that the biological
grafts used offer reliable long-term patency without permanent
anticoagulation, and no complications related to graft thrombosis
or infection. One limitation of this study is the absence of imaging
to document long-term patency of the IVC reconstruction in six
patients. Imaging for this review was available for 26 of the 32
patients at a median follow-up of 40 months after the IVC repair.
However, there were no patients who developed signs or symp-
toms of IVC obstruction. For the remaining living patients, the
cumulative 3-year patency for IVC graft replacement, determined
by imaging and/or clinical assessment was 100%. With the het-
erogeneity of tumour types included in the present series it is
difficult to comment definitively on the oncological efficacy of this
radical approach for individual cancer subsets. However, the
overall 5-year survival of 48% clearly suggests that radical vena
caval resection requiring reconstruction has an oncological
benefit for this select group of patients who would otherwise have
no chance of a cure.
The clinical results of this series are similar in many aspects to
other recent series of IVC reconstruction with PTFE grafts.1–5
However, biological grafts allow superior flexibility and greater
biocompatability, especially in light of their easier handling and
long-term patency without permanent anticoagulation. These
clear advantages of biological grafts should lead to their wider use
in IVC replacement surgery.
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